<DOC>
	<DOC>NCT02409368</DOC>
	<brief_summary>The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or after at least 1 systemic therapy.</brief_summary>
	<brief_title>An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com ECOG Status: PS 01 &amp; PS 2 Subjects with histologically or cytologicallydocumented SqNSCLC Subjects must have experienced disease progression or recurrence during or after one prior platinum doubletbased chemotherapy regimen Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria Subjects with treated or asymptomatic CNS metastases Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, nonpalliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab Males and Females, ages 18 or older Subjects with untreated, symptomatic CNS metastases Subjects with carcinomatous meningitis Subjects with active, known or suspected autoimmune disease. Subjects who received prior therapy with antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody (including ipilimumab or any other antibody or drug specifically targeting Tcell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>